Proteinase-Activated Receptor-1 and Immunomodulatory Effects of a PAR1-Activating Peptide in a Mouse Model of Prostatitis

Figure 8

Administration of the PAR1 activating peptide TFLLR-NH₂ elicits non-PAR1-mediated effects in the mouse prostate. Prostates were treated with HEPES vehicle in wild-type mice (HEPES), ethanol + dinitrobenzene sulfonic acid in wild-type mice (EtOH + DNBS), ethanol + dinitrobenzene sulfonic acid in PAR1 knockout mice (EtOH + DNBS PAR1^−/−), or ethanol + dinitrobenzene sulfonic acid + PAR1 activating peptide TFLLR-NH₂ in PAR1 knockout mice (EtOH + DNBS + PAR1 TF PAR1^−/−) for 2 days. The inflammatory response was measured by monitoring (a) macroscopic prostate damage, (b) microscopic prostate damage, (c) percent prostate weight, and (d) myeloperoxidase (MPO) activity. Data are mean ± SEM of 𝑛=5-6 per group. *𝑃<0.05, ^∗∗𝑃<0.01, and ^∗∗∗𝑃<0.001 for treatment groups versus HEPES; ^∧∧𝑃<0.01, ^∧∧∧𝑃<0.001 for treatment groups versus EtOH + DNBS + PAR-1 TF PAR1^−/−.

(a)

(b)

(c)

(d)